Taken together, these findings suggest that BrMSCs and/or saroglitazar could inhibit BLM-activated TGF-β1/SMAD signaling pathway in pulmonary fibrosis with a remarkable role of PPARγ/α (Table 3, Fig. 4). Here, PPARG is linked to pulmonary fibrosis.